Trump delays tariff hike suggesting progress on US-China trade talks

Yesterday, an extended week of talks between the US and China on trade issues ended, that were commented by US President Trump as “productive” and also on the Chinese side, the press reported substantial progress.

Highlights:

  • On Sunday, US President Trump announced that he would delay to an unspecified date the tariff increase on imports from China which were scheduled to start on March 1.
  • Trump acknowledged “productive” trade talks and also the Chinese press reported substantial progress. Trump and Xi are reportedly planning to meet for a summit later in March at Trump’s Mar-a-Lago resort.
  • Details about the progress were not given. News from last week point to steps forward to narrow the bilateral trade deficit as well as on ensuring intellectual property rights and tackling alleged forced technology transfer.
  • The postponement of the deadline increases the chances of a deal and reduces the risk of a further escalation of the trade conflict, an important source of current global uncertainty. However, given the complexity of the matter, a positive negotiation result is not a done deal yet and existing tariffs could well be maintained for some time.
  • The Chinese stock market rallied on the news and the Chinese currency appreciated versus the US-dollar.

Download the full publication below

TRUMP DELAYS TARIFF HIKE SUGGESTING PROGRESS ON US-CHINA TRADE TALKS

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.